

ASX Announcement



Medibio Limited – 10 June 2020

Section 708A Cleansing Notice

The Directors of Medibio Limited (ASX: MEB, “**Medibio**” or the “**Company**”) advise that it issued 16,333,333 fully paid ordinary shares (**Shares**) at two issue prices as outlined within the Appendix 2A’s released to the market on 2 June 2020 for settlement of services provided to the Company in addition to a settlement of a joint venture dispute as announced on 27 May 2020.

The Company confirms that:

- (a) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) the Company is providing this notice under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) section 674 of the Corporations Act as it applies to the Company; and
- (d) as at the date of this announcement, there is no excluded information of the type referred to in Section 708A(7) and 708A(8) of the Corporations Act.

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

Melanie Leydin
Director and Company Secretary
Medibio Limited

For further information, please contact Ms Leydin on +61 3 9692 7222